# Clinical Outcome Assessments in Implant Dentistry Clinical Research

## TL;DR

This paper clarifies terminology and standards for measuring outcomes in implant dentistry to improve research quality and consistency.

## Contribution

The paper introduces a framework aligning implant dentistry outcomes with FDA-recognized clinical outcome assessments and emphasizes content validity.

## Key findings

- Clinical outcome assessments (COAs) in implant dentistry are positioned between definitive events and objective biomarkers.
- Content validity and co-development with patients are essential for reliable COAs.
- Standardized definitions can enhance the meaningfulness and comparability of implant dentistry trials.

## Abstract

Precise terminology and a clear distinction between what is measured (outcomes) and how it is measured (outcome assessments) are fundamental in implant dentistry (ID) research. This narrative review defines outcomes and outcome assessments and aligns ID terminology with established regulatory frameworks. We map survival outcomes, biomarkers, and the four FDA‐recognized clinical outcome assessments (COAs) patient‐reported, clinician‐reported, observer‐reported, and performance outcomes onto a spectrum defined by patient meaningfulness and the need for human judgment. Definitive events (e.g., implant loss) sit at one end of the spectrum, and purely objective biomarkers (e.g., dimensional ridge changes) sit at the other end, while COAs occupy the middle of that spectrum. Content validity is essential for any COA. Tools must be co‐developed with people with lived experience (PWLE) and evaluated with Consensus‐based Standards for the selection of health Measurement INstruments (COSMIN) standards to ensure they truly measure the intended construct, in the right population, with adequate reliability, responsiveness, and interpretability. Finally, we caution against conflating measures (tools, e.g., radiography) with endpoints (prespecified analysis variables with time frame and threshold). Using standardized definitions in present and future ID consensus statements will increase their meaningfulness and strengthen the relevance and comparability of clinical trials.